Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

Medytox

Status and phase: Completed; Phase 1

Conditions: Hyperhidrosis; Anhidrotic Area

Treatments: Drug: Botox; Drug: Meditoxin

Study type: Interventional

Funder types: Industry

Identifiers

NCT03647982

MT01-KR17PAH110

Details and patient eligibility

About

To determine the anhidrotic area and safety of MEDITOXIN

Enrollment: 13 patients

Sex: Male

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male adults aged between 20 and 45 years

Exclusion criteria

• Subjects not appropriate for participating in this study according to the investigator's opinion

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

13 participants in 6 patient groups

botulinum toxin 1U

Experimental group

Treatment:

Drug: Botox

Drug: Meditoxin

botulinum toxin 3U(25U/1ml)

Experimental group

Treatment:

Drug: Botox

Drug: Meditoxin

botulinum toxin 5U

Experimental group

Treatment:

Drug: Botox

Drug: Meditoxin

botulinum toxin 10U

Experimental group

Treatment:

Drug: Botox

Drug: Meditoxin

botulinum toxin 3U(50U/1ml)

Experimental group

Treatment:

Drug: Botox

Drug: Meditoxin

botulinum toxin 3U(12.5U/1ml)

Experimental group

Treatment:

Drug: Botox

Drug: Meditoxin